Emergency Medicine Cases – Where the Experts Keep You in the Know. For complete episodes please visit emergencymedicinecases.com
Mark A. Socinski, MD - Expanding Options, Lingering Questions: How to Select the Right Immunotherapy for First-Line Treatment of Advanced NSCLC
Manage episode 329436730 series 103590
Player FM과 저희 커뮤니티의 PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education 콘텐츠는 모두 원 저작자에게 속하며 Player FM이 아닌 작가가 저작권을 갖습니다. 오디오는 해당 서버에서 직접 스트리밍 됩니다. 구독 버튼을 눌러 Player FM에서 업데이트 현황을 확인하세요. 혹은 다른 팟캐스트 앱에서 URL을 불러오세요.
Go online to PeerView.com/JBW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitors (ICIs) comprise a critical component of the treatment arsenal for advanced/metastatic non–small cell lung cancer (NSCLC), with numerous single-agent and combination options approved for use in the first-line setting. Despite the availability of a broad array of immunotherapy options, not all patients benefit from or have access to these agents, especially those in underserved populations and communities. Innovative solutions are needed to help address some of the challenges and improve access to level the playing field for more patients with advanced/metastatic NSCLC. In this educational activity based on a recent web broadcast, experts provide useful clinical updates and multifaceted practical guidance for navigating the multitude of immunotherapy options for newly diagnosed patients with advanced/metastatic NSCLC. Upon completion of this activity, participants should be better able to: Compare the characteristics of available and emerging immunotherapy-based strategies for first-line treatment of advanced/metastatic nonsquamous NSCLC, Individualize first-line selection of immunotherapies or combinations for patients with advanced/metastatic NSCLC based on all relevant factors related to the tumor, disease, patient, and treatment, Implement patient-centric, team-based approaches to integrate immunotherapy for eligible patients with advanced/metastatic nonsquamous NSCLC, considering current evidence and guidelines, including the applicability and implications of data from different patient populations.